Citigroup’s Artiva Biotherapeutics ARTV Stock Holding History

Citigroup’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.8K	Buy	+2,143	New	+$19.5K	﹤0.01%	5146
2025 Q4	–	Sell	-105,573	Closed	-$303K	–	6568
2025 Q3	$303K	Buy	105,573 +102,006	+2,860%	+$273K	﹤0.01%	3805
2025 Q2	$5.39K	Sell	3,567 -10,771	-75%	-$22.6K	﹤0.01%	5271
2025 Q1	$43K	Sell	14,338 -1,268	-8%	-$6.85K	﹤0.01%	4917
2024 Q4	$157K	Buy	15,606 +5,425	+53%	+$65.2K	﹤0.01%	4568
2024 Q3	$157K	Buy	+10,181	New	+$118K	﹤0.01%	4518

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Citigroup's ARTV Position: Q2 2026 in Review

Citigroup opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 2,143 shares worth $20.8K. The stake represents ﹤0.01% of the portfolio and ranks #5146 among its holdings. This is a return to the name: Citigroup previously reported a position in ARTV as recently as Q3 2025.

Citigroup first reported a position in ARTV in Q3 2024 and has held it in 6 quarters since. The position peaked at $303K in Q3 2025. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

Citigroup held 2,143 shares of Artiva Biotherapeutics worth $20.8K as of Q2 2026.
Artiva Biotherapeutics was a new Citigroup position in Q2 2026.
Artiva Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5146 holding.
Citigroup first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 6 quarters since.
Citigroup's Artiva Biotherapeutics position peaked at $303K in Q3 2025.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.